The ABI2 Knockout Huh-7 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population engineered for targeted disruption of the ABI2 gene in Huh-7 human hepatocellular carcinoma cells. This polyclonal pool offers a heterogeneous knockout background, avoiding clonal artifacts while enabling functional loss-of-function studies in a liver cancer context. The editing process introduces gene-inactivating mutations without selection for single-cell clonality, thereby providing a robust model for population-level analyses.
Huh-7, an epithelial cell line isolated from a well-differentiated hepatocellular carcinoma of a 57-year-old Japanese male in 1982, is widely used for HCV replication, hepatic metabolism, drug toxicity, and cancer research. Its hepatocyte-like features and stable growth make it an excellent platform for investigating cytoskeletal dynamics such as cancer cell motility in a disease-relevant setting.
ABI2 (Abelson interactor 2) encodes an adaptor protein that links activated receptor tyrosine kinases (EGFR, PDGFR) and Rac1 GTPase to the WAVE regulatory complex. Upon Abl kinase-mediated phosphorylation, ABI2 recruits the WAVE complex (WASF1-3, CYFIP1, NCKAP1) and the Arp2/3 complex to stimulate branched actin polymerization, driving lamellipodia formation and cell migration. Key interacting partners include ABL1, ABL2, WASF1, and EPS8, among others. This signaling axis integrates growth factor and adhesion cues to promote membrane protrusion and endocytic trafficking.
In hepatocellular carcinoma, ABI2 upregulation correlates with increased metastatic potential. The Huh-7 knockout model enables dissection of ABI2??s role in HCC migration and invasion, as loss of ABI2 is predicted to impair WAVE complex-driven actin remodeling and reduce lamellipodia formation. Additionally, these cells may help elucidate host cytoskeletal contributions to HCV replication and pathogenesis, given Huh-7??s permissiveness for the virus.
These polyclonal knockout cells are ideally suitable for motility assays (wound healing, Transwell), actin cytoskeleton visualization (phalloidin staining), and biochemical analyses of WAVE complex integrity (co-immunoprecipitation). Applications also include cell proliferation and drug sensitivity screens to evaluate ABI2 as a therapeutic target, as well as signal transduction studies via phospho-ABL immunoblotting. For further information or ordering inquiries, please contact Ascent Research directly.
